Speaker 01
Prof. Chantal Abergel
Read more…
Speaker 05
Dr. D.L. (Bart) Haagmans
Speaker 02
Prof. Zhengli Shi
Wuhan Institute of Virology, China
Prof. Shi is the director of the Center for Emerging Infectious Diseases of the Wuhan Institute of Virology. She got her Ph.D training at Montpellier University II, France, from 1996 to 2000. Her research focuses on viral pathogen discovery through traditional and high-throughput sequencing techniques. She has been studying the wildlife-borne viral pathogens, particularly bat-borne viruses since 2004. Her group has discovered diverse novel viruses/virus antibodies in bats, including SARS-like coronaviruses, adenoviruses, adeno-associated viruses, circoviruses, paramyxoviruses and filoviruses in China. One of her great contributions is to uncover genetically diverse SARS-like coronaviruses in bats with her international collaborators and provide unequivocal evidence that bats are natural reservoirs of SARS-CoV. She has coauthored >130 publications on viral pathogen identification, diagnosis and epidemiology.
Speaker 04
Prof. Vincent Racaniello
Speaker 03
Prof. Linda Saif
Read more…
Speaker 06
Prof. Stanley Perlman
Speaker 06
Dr. Anne Balkema-Buschmann
Speaker 06
Robert C. Gallo, MD
Robert C. Gallo, MD, is Co-Founder and Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine, Baltimore, and Co-Founder and International Scientific Advisor of the Global Virus Network (GVN)
He is recognized internationally for his co-discovery of HIV as the cause of AIDS. As a biomedical research scientist, he since has spent much of his career working to eliminate AIDS and other viral chronic diseases. In the early 1980s, Gallo and his team also pioneered the development of the HIV blood test, which enabled healthcare labors to screen for the AIDS virus for the first time, leading to a more rapid diagnosis while simultaneously protecting patients receiving blood transfusions. His research also helped physicians develop HIV therapies to prolong the lives of those infected with the virus. His 1996 discovery that a natural compound known as chemokines can block the HIV virus and halt the progression of AIDS was hailed by Science magazine as one of that year’s most important scientific breakthroughs.
Speaker 06
Prof. Covadonga Alonso Martí
Professor of Research at CSIC-INIA Dpt. Biotechnology
Covadonga Alonso MD PhD is Professor of research at Consejo Superior de Investigaciones Científicas,Dpt. Biotechnology of INIA, Madrid, Spain. Her group is interested in finding new targets for antivirals against highly pathogenic viruses from a One Health perspective. We focus in finding common targets for SARS-CoV-2, Ebola, and African swine fever virus, based on host-pathogen interactions and innate immunity studies. Our working model has been African swine fever virus (ASFV) in which we have identified cellular molecules that are crucial for viral infection at several levels, including viral entry/uncoating and transport, replication, autophagy, and lipid regulation. This agent causes an acute deadly infection in domestic pigs with a high socio-economic impact in Europe and Asia nowadays. Our goal is to increase knowledge on the mechanisms required for infection in order to find targets for new vaccination and antiviral strategies. I have been Chair of Asfarviridae study group of the ICTV, CEO of the Global African swine fever Research Alliance (GARA) and acting Vicepresident of the Board of the Spanish Society for Virology, between others.
Speaker 06
Prof. Murilo Zerbini
President of the International Committee on Taxonomy of Viruses (ICTV); Department of Phytopathology at UFV, Brazil
I’m an Agronomist (UFV, Brazil) with a Ph.D. in Plant Pathology (UC Davis, 1996). I started working as an assistant professor at the Department of Plant Pathology at UFV in 1996, becoming a full professor in 2014. My early work was mostly on potyviruses (plant RNA viruses transmitted by aphids), studying virus-host interactions and obtaining transgenic passionfruit plants resistant to woodiness disease. Unfortunately these plants (which were immune to the disease) were never approved for field testing and the work was abandoned in the early 2000’s. Nowadays, my main area of research is the ecology and evolution of begomoviruses (plant ssDNA viruses transmitted by whiteflies). We study viral population in both cultivated and non-cultivated hosts, and are specially interested in the factors that affect spillover from non-cultivated plants to crops. I was editor-in-chief of Tropical Plant Pathology from 2012 to 2017, and associate editor of Archives of Virology, Annals of Applied Biology, Journal of General Virology, Plant Pathology and Virology. I’m currently an Associate Dean of Graduate Studies at UFV. I’ve been involved in virus taxonomy for almost 20 years, initially as a member of both the Potyviridae and Geminiviridae study groups of the International Committee on Virus Taxonomy (ICTV). I was elected to the Executive Committee of the ICTV in 2014, became chair of the Plant Virus subcommittee in 2017, and was elected President of the ICTV in 2020.
Speaker 06
Dr. Andrea Maria Marzi
NIAID Laboratory of Virology, Germany
Dr. Marzi received her Ph.D. in virology from the Friedrich-Alexander University Erlangen-Nurnberg, Germany in 2007 where she studied the glycoprotein-mediated entry of Ebola virus (EBOV) and HIV. Later that year Dr. Marzi moved to Winnipeg, Canada to join Dr. Heinz Feldmann’s group at the National Microbiology Laboratory, Public Health Agency of Canada to work in the BSL4 laboratory on filoviruses and EBOV vaccines.
Read more…
In 2008, Dr. Marzi moved with Dr. Feldmann to the NIAID Rocky Mountain Laboratories, Hamilton, MT and continued her BSL4 work on vaccine development for highly pathogenic viruses using primarily the vesicular stomatitis virus (VSV) platform. She also studied the pathogenesis of filoviruses and developed small animal models for these pathogens. Recently, she expanded the VSV vaccine platform to other emerging pathogens like Zika virus. In 2013, Dr. Marzi was promoted to Staff Scientist, and in 2017 to Associate Scientist. Dr. Marzi was selected as a tenure-track investigator in the NIAID Laboratory of Virology in 2019.
The German Society of Virology recognized Dr. Marzi with the prestigious Loeffler-Frosch Award for her research on filoviruses and vaccine development in 2019.
Speaker 06
Prof. Edward Holmes
ARC Australian Laureate Fellow, Brazil
Professor Eddie Holmes is known for his work on the evolution and emergence of infectious diseases, particularly the mechanisms by which RNA viruses jump species boundaries to emerge in humans and other animals. He currently holds an ARC Australian Laureate Fellowship. He moved to the University of Sydney in 2012. He has studied the emergence and spread of such pathogens as SARS-CoV-2, influenza virus, dengue virus, HIV, hepatitis C virus, myxoma virus, RHDV and Yersinia pestis. His previous appointments include Verne M. Willaman Chair in the Life Sciences at the Pennsylvania State University, USA, and Affiliate Member of the Fogarty International Centre (2005-2012), National Institutes of Health, USA. From 1999-2004 he was Fellow of New College, Oxford. He is also an Honorary Visiting Professor at Fudan University, Shanghai. He is the author of 629 peer-reviewed papers and two books. His publications have >84,000 citations (h-index of 142, i10-index of 561; see http://scholar.google.com.au/citations?user=Syrp1IMAAAAJ&hl=en)
Speaker 06
Prof. Marion Koopmans
Head of the Viroscience Department of Erasmus Medical Center in Rotterdam and collaborator in the COVID-19 Data Portal project, The Netherlands
Professor Marion Koopmans, DVM PhD focuses on global population level impact of rapidly spreading zoonotic virus infections, with special emphasis on foodborne transmission. Her research focuses on unravelling the modes of transmission of viruses among animals and between animals humans, and the use of pathogenic genomic information to unravel these pathways and to signal changes in transmission or disease impact. She is scientific coordinator of COMPARE, a large H2020 funded project (20 MEuro), exploring the potential uses of next generation sequencing techniques for outbreak detection and tracking (www.compare-europe.eu), and co-PI in the FP7 funded PREPARE project (www.prepare-europe.eu) aimed at building a pan-European operational network for rapid and large-scale European clinical research in response to infectious disease outbreaks with epidemic potential. Read more…
Speaker 06
Dr Jerome Kim
Director General of the International Vaccine Institute, South Korea
Jerome H. Kim, MD is the Director General of the International Vaccine Institute (IVI). Dr. Kim led the US Army’s RV144 HIV vaccine trial in Thailand, the first demonstration that an HIV vaccine could prevent human infection and subsequent work identifying immunological and virological correlates. He rose to become the Principal Deputy, US Military HIV Research Program, and Project Manager, HIV Vaccinesm US Army Medical Materiel Development Agency. Read more…
In 2015 he retired from the US Army and became the 3d Director General of the International Vaccine Institute (IVI). The IVI was founded in 1997 and is the first international organization headquartered in the Republic of Korea. It counts 35 signatory countries and the World Health Organization as supporters. The IVI’s 130 employees work to accelerate R&D in vaccines for Global Health in over 30 countries with collaborators from Korea, Asia and around the world. During Dr. Kim’s tenure IVI’s oral cholera vaccine, produced by a Korean company (EuBiologics), was prequalified, and EuBiologics production of Euvichol has contributed greatly to the worldwide surge in OCV use to prevent cholera. Collaboration with the Bill & Melinda Gates Foundation, SK Chemicals (Korea) and BioFarma (Indonesia) have brought IVI’s new typhoid conjugate vaccine to Phase II testing. IVI has been critical in generating much needed information on the burden and cost of typhoid (enteric fever) worldwide through the Gates-funded TSAP and SETA programs. IVI’s laboratory is working on new vaccines against Shigella, Salmonella, tuberculosis, the Middle East Respiratory Syndrome, hepatitis A, and adenovirus. IVI’s $30M annual budget comes from state funders (Korea, Sweden, India), philanthropies (Bill and Melinda Gates Foundation, Samsung Life Public Welfare Foundation, Wellcome Trust), US NIH, the European and Developing Countries Clinical Trials Partnership, and Korean private donors through the Korea Support Committee for IVI.
The author of over 250 publications and 11 patents, Dr. Kim graduated with highest honors in Biology and high honors in History from the University of Hawaii, where he won the Arthur Lyman Dean Prize in the Humanities and the Library Prize for Pacific Islands Area Research. He then attended the Yale University School of Medicine and trained in Internal Medicine and Infectious Diseases at Duke University Medical Center. He became a full Professor of Medicine at the Uniformed Services University of the Health Sciences in 2012. Since leaving the military Dr. Kim became an adjunct Professor in the Department of Medicine, Uniformed Services University of the Health Sciences, the Graduate School of Public Health, Seoul National University, and Yonsei University. In addition to several honor societies, including Phi Beta Kappa and Alpha Omega Alpha, in 2013 he received the John Maher Award for Research Excellence, USUHS, and the Department of the Army R&D Achievement Award for Technical Excellence. Dr. Kim is a Fellow of the American College of Physicians and the Infectious Diseases Society of America. He has been listed among the 50 most influential persons in vaccines and serves on scientific advisory groups to private and public organizations, the World Health Organization, and Gavi, the Vaccine Alliance.
Speaker 06
Dr. Teresa de los Santos
Senior Scientist, Plum Island Animal Disease Center, North East Area, Agricultural Research Service, U.S. Department of Agriculture
Teresa de los Santos is a senior scientist at the Foreign Animal Disease Research Unit at Plum Island Animal Disease Center in Orient, NY. She holds a BS in Biochemistry from the University of Buenos Aires, Argentina, a MA in Microbiology from Columbia University, NY. and a PhD in Biological Chemistry from the University of Buenos Aires, Argentina and Stony Brook University, NY, USA.
Since 2003, Teresa has been working at the Foreign Animal Disease Research Unit (FADRU), Plum Island Animal Disease Center, of the Agricultural Research Service at the US Department of Agriculture.
Read more…
Her research is mainly focused toward the understanding of the molecular mechanisms involved in the Foot and Mouth Disease Virus blockade of the host innate immunity. In particular, Dr de los Santos has discovered multiple functions of the FMDV leader protein. This knowledge has been applied toward the development of novel vaccines and biotherapeutics that are currently under development to effectively control FMD and in some instances, other viral diseases of livestock.
Dr de los Santos has authored over 60 publications in peer-reviewed journals, has written several book chapters, filed 5 patents, presented seminars in American and International Universities such as Kansas State University, Texas A&M, U. of Connecticut, U. of Maryland, University of Pretoria in South Africa, Autonomous University of Madrid, Spain, U. of Buenos Aires, Argentina, FMD World Reference Lab at the Pirbright Institute in UK, the National Institute of Technology and Agriculture in Argentina, the Center for Animal Health Research (CISA), National Institute for Agricultural and Food Research and Technology (INIA) in Spain, etc. She has been an adjunct professor in Texas A&M since 2014. She is a member of: The American Society of Microbiology; The American Society of Virology; The American Association for the Advancement of Science; The executive committee of the Global Foot and Mouth Research Alliance (GFRA)
Speaker 06
Prof. Jean Rommelaere
Honorary Professor, Clinical Cooperation Unit “Virotherapy”, DKFZ, Germany
Jean Rommelaere is former Head of the Tumor Virology Division at the German Cancer Research
Center (DKFZ), and former Director of two Research Units at the French National Institute of Health
and Medical Research (INSERM) in Heidelberg, Germany. His professional career comprises steps
in Belgium (PhD holder, qualified researcher and lecturer at the Free University of Brussels-ULB),
USA (post-doctoral fellow at the Massachusetts Institute of Technology, Cambridge, and Yale
University School of Medicine, New Haven), France (INSERM Research Director at the Pasteur
Institute, Lille), and Germany (professor at the University of Heidelberg). As a result of his initial
activities in the field of DNA replication and repair, he became interested in using viruses to probe
these processes and their deregulation in malignantly transformed cells. Over the past 25 years, his
research has focused more particularly on the interactions between parvoviruses and transformed
cells, and on the development of oncolytic parvoviruses as potential cancer therapeutics. He has
published more than 250 scientific papers and reviews in peer-reviewed journals and books.
Speaker 06
Prof. Mylène Ogliastro
INRA Research Director, University of Montpellier, France
My main interests are insects and viruses, looking at their interactions at different levels, from molecules to communities. One of my particular focus is to develop new virus-based strategies to specifically control insects. This application of virology requires a deep understanding of basic virology issues, ie what determines host range and specificity and how these interactions evolve. The models we work with in the lab are caterpillars (Spodoptera sp) and small single stranded naked DNA viruses (densoviruses).
As a main issue for orally transmitted viruses is to cross the gut of their host. Viruses are wonderfull vehicules to explore “The Inside Story of body’s Most Underrated Organ”. The gut is beautifull!
Speaker 06
Prof. Klaus Hedman
Professor in Clinical Virology, University of Helsinki, Finland
Klaus Hedman, MD, Professor of Clinical Virology and Chief Physician, has elucidated the pathogenesis of infectious diseases and invented methods for their diagnosis. His team introduced the measurement of IgG-avidity into virus and parasite diagnostics. They currently work on (i) newly discovered human DNA viruses, (ii) a revolutionary FRET-based homogenous (wash-free, single-step) point-of-care serodiagnostic concept, and (iii) the occurrence of viral nucleic acids in ancient human tissue remains (archeovirology).
Speaker 06
Prof. Marietjie Venter
Department Medical Virology, University of Pretoria, South Africa
Marietjie Venter obtained her PhD(Medical Virology) through Wits (2003) on Respiratory Syncytial Virus and received postdoctoral training at the National Institute for Allergy and Infectious Diseases, USA(2003) on West Nile virus. She worked on respiratory- and zoonotic arboviruses since 1999, as medical scientist at the National Institute for Communicable diseases, (NICD) National Health laboratory Services (NHLS) and University of Pretoria. From 2009-2014 she was co-director, Centre for Respiratory diseases and Meningitis, NICD and Director, National Influenza Centre at the NICD. From 2014-2016 she worked for the US-Centers of Disease Control and Prevention (US-CDC), Global Disease Detection Centre, South Africa as One Health Program director. Read more…
Speaker 06
Prof. Hanu Pappu
Department of Plant Pathology. Washington State University, USA
Hanu Pappu was born in India. He obtained his B.S. degree in agriculture from the Agricultural College, Bapatla, in 1982 and an M.S. degree in plant pathology with Anupam Varma from the Indian Agricultural Research Institute, New Delhi, in 1985. He earned his Ph.D. degree in plant science with Chuji Hiruki from the University of Alberta, Edmonton, in 1990. After his post-doctoral work with Charles Niblett at the University of Florida, he joined the University of Georgia as an assistant professor and was promoted to associate professor. In 2002, Pappu joined Washington State University (WSU), Pullman, as an associate professor and was promoted to full professor in 2010. He holds the Samuel H. Smith Distinguished Professorship at WSU. Pappu served as department chair for 5 years, from 2008 to 2013. Pappu leads a highly productive and internationally recognized research program in genomics and biotechnology of RNA and DNA viruses that are economic constraints to the production of several horticultural and field crops. He has published more than 172 refereed journal articles, including 100 in the last 10 years, and 14 invited review articles. He has given 34 invited presentations at national and international conferences and obtained more than $5 million in competitive extramural grants in the last 5 years. Read more…
Citrus tristeza virus (CTV) is considered one of the most important viral pathogens of tree fruits, and Pappu was the first to decipher its genome structure and organization and structure–function relationships. His work laid the foundation for subsequent research on the molecular biology and host–CTV interactions.
Pappu is especially noted for his research on thrips-transmitted tospoviruses. Globally, these viruses cause more than $1 billion in crop losses annually to field and horticultural crops. Pappu developed an internationally recognized research and extension program on Tomato spotted wilt virus (TSWV), the most common and economically important tospovirus in the United States. He has published more than 50 refereed articles on TSWV and contributed to diagnostics and IPM for this pest complex. He was part of a team that field-tested transgenic peanut for TSWV resistance and developed a risk index for TSWV in peanut that was adopted by more than 80% of peanut growers in Georgia. He was the first to characterize a new tospovirus from watermelon that was a significant constraint to cucurbit production in parts of Asia. His findings provided clarity for tospovirus identification and paved the way for improved virus diagnostics and management.
In 2003, Pappu reported Iris yellow spot virus (IYSV) on onion in Washington State and, by 2005, it became the number one constraint on onion production in the Pacific Northwest. Pappu developed descriptors for virus strains, new experimental hosts for studying virus biology, improved screening protocols, and new detection tools and applied them to understand the epidemiology of the virus. Further, he evaluated and identified onion varieties with tolerance and developed a national network for IYSV surveillance and response. Pappu used IYSV and TSWV to investigate intervirus interactions at the molecular level in dually infected plants. He was the first to show genetic complementation between two viruses that resulted in the expansion of the host range, and his findings identified a new role for the viral gene-silencing suppressor in potentially modulating the biology and host range of tospoviruses. Using next generation sequencing technologies, Pappu was the first to obtain information on the origin, distribution, and abundance of TSWV-specific small RNAs. The findings could advance our understanding of the differential processing of vsiRNAs in antiviral defense and viral pathogenicity. His research on the genomics and proteomics of tospovirus infections has contributed to an increased understanding of virus–host interactions at the molecular level. His group prepared the first-ever protein interaction maps for tospoviruses in mixed infections. His recent research on using artificial microRNA-based approaches to trigger virus resistance in plants has opened up new possibilities for introducing broad-spectrum virus resistance.
Nursery and ornamental industry in the United States is valued at more than $5 billion and viruses are of quarantine concern affecting interstate and international commerce. Pappu identified and characterized new viruses infecting dahlia and developed molecular methods for their detection. His fundamental research has shown the existence of endogenous caulimoviral sequences and showed that these integrated viral sequences are present in cultivated ornamentals and in wild relatives at their center of origin.
Potato is Washington’s third largest crop, contributing more than $3.5 billion annually to the state’s economy. Pappu was the first to show that infection by Potato virus S (PVS) could result in the breakdown of late blight resistance. His research into genetics of this interaction identified a potential source of linkage between late blight resistance and virus susceptibility. His findings have important implications for potato breeding programs worldwide since PVS is a common potato virus and could compromise late blight resistance.
Pappu teaches two undergraduate courses (General Plant Pathology; Agricultural Food Systems) and a graduate course (Plant Virology). He was recognized by WSU as Mentor of the Year and Advisor of the Year. His contributions to the success of the department as one of the most productive units in the college were recognized with the Dean’s Meritorious Service Award. Pappu’s mark on the Plant Pathology Department cannot be overstated. As chair, he built the graduate program into the largest in the nation. In recognition of his international standing, Pappu was elected secretary of the International Working Group on Viruses of Legumes and Vegetables. He was invited to serve on the organizing committees of the International Symposium on Plant Virus Epidemiology and the International Symposium on Thysanoptera and Tospoviruses, and he was an invited participant in workshops organized by the Gates Foundation and FAO in Africa. He served as a reviewer of grant proposals from several countries and served on grant review panels of USDA, NSF, and the U.S. National Academies. Pappu’s outstanding and sustained record of research, teaching, extension, outreach, service, and administration make him highly deserving of the APS Fellow Award.
Speaker 06
Prof. Khatijah Yusoff
Professor in Microbiology, Universiti Putra Malaysia, Malaysia
Khatijah Yusoff obtained a BSc in Microbiology in 1979 and PhD in 1983 from La Trobe University,
Australia. She joined Universiti Putra Malaysia as a lecturer and became a full Professor in 2001.
Since then, she has held various administrative posts including the Dean of Faculty of Biotechnology
and Biomolecular Sciences and the Deputy Vice-Chancellor (Academic & International Affairs). From
2008-2010, she was seconded to the Ministry of Science, Technology and Innovation Malaysia as the
Deputy Secretary-General (Science). She is a Council member of the Academy of Sciences Malaysia
(ASM), Vice-President of the Islamic World Academy of Sciences (IAS) and Vice-President of The
World Academy of Sciences (TWAS).Read more…
International Centre for Genetic. Engineering and Biotechnology (ICGEB). In 2010, she was awarded
DSc (honoris causa) by her alma mater, La Trobe University. Her main research focus is on the
development of Newcastle disease virus (NDV) vaccines and diagnostics. Being a poultry virus, this
virus has minimal side effects on humans, thus making the vaccine she is developing safe and
effective. Moreover, the NDV strain being used is heat stable and will not require any cold chain for
delivery.
Speaker 06
Prof. Heikki Hyöty
Professor of Virology, Tampere University, Finland
Heikki Hyöty is working as the full-time professor of virology at the Tampere University, Finland. He has graduated in medicine, made his PhD in virology, and his principal research interest is the role of microbes in immune-mediated diseases, particularly type 1 diabetes. He has studied interactions between viruses and immune system and their contribution to the development of human type 1 diabetes. His scientific contributions include the first prospective studies evaluating viral etiology of type 1 diabetes and leading to the identification of the association between enterovirus infections and initiation of the beta-cell damaging process. He has contributed to the development of other innovative research strategies, e.g. the collection of pancreas tissues from cadaveric organ donors with type 1 diabetes and studies in unique ecological settings in populations that share the same ancestry but live in contrasting environments (Karelian Republic of Russia and Finland). Read more…
Speaker 06
Prof. Kanta Subbarao
Director of the WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne, Australia
Professor Kanta Subbarao was appointed Director of the WHO Collaborating Centre for Reference and Research on Influenza in 2016. Prior to her arrival in Melbourne, she was Chief of the Emerging Respiratory Viruses Section of the Laboratory of Infectious Diseases, NIAID, National Institutes of Health (NIH) in the United States from 2002-2016 and chief of the Molecular Genetics Section of the Influenza Branch at the US CDC from 1997-2002.
Read more…
Kanta is a virologist and a physician with specialty training in pediatrics and pediatric infectious diseases. She received her M.B.B.S. from Christian Medical College, Vellore in India, completed training in pediatrics and pediatric infectious diseases in the US and earned an M.P.H. in epidemiology from the University of Oklahoma Health Sciences Center and received postdoctoral training in the Laboratory of Infectious Diseases, NIAID, NIH.
Her research is focused on newly emerging viral diseases of global importance including pandemic influenza, severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) and includes study of virus biology and pathogenesis, immune responses to infection and vaccination, development and preclinical and clinical evaluation of vaccines.
Speaker 06
Prof. Evgeny Nikolaev
Professor, Center for Computational and Data-Intensive Science and Engineering, Center for Translational Biomedicine, Skoltech, Russia
Prior to Skoltech, Evgeny was a professor of chemical physics and led the Laboratory of Ion and Molecular Physics at the Institute of Energy Problems of Chemical Physics of the Russian Academy of Sciences.
At the same time, he worked as the head of the Laboratory for Mass Spectrometry of Biomacromolecules at the Institute of Biochemical Physics of the Russian Academy of Sciences. Outside of that position, Evgeny was the lead scientific member of the Orehovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences. Previously he has researched at the Institute of Chemical Physics of the Russian Academy of Sciences.
Read more…
Evgeny has also taken up organizational roles, serving as an organizer of the 8th European Conference on Mass Spectrometry and a member of the organizational committee for other European conferences on mass spectrometry. He has organized three Moscow conferences for schools on Mass Spectrometry and participated as a member of the organizational committee for three international conferences on Genome, Proteomics, Bio-informatics, and Nanobiotechnology for Medicine. He has also organized the first International Skolkovo Conference for imaging with mass spectrometry.
His bachelor’s degree in molecular and chemical physics and his Ph.D. in chemical physics are from the Moscow Institute of Physics and Technology. He holds the title “doctor of science” from the Institute of Energy Problems of Chemical Physics of Russian Academy of Sciences.
Evgeny has been a visiting professor throughout the world: University Metz, France; University of Waterloo, Canada; University of Delaware, USA; University of Arizona, USA; and Purdue University, USA.
He is a member of the editorial board for the European Journal of Mass Spectrometry and Rapid Communications in Mass Spectrometry. He has advised 20 Ph.D. students at Moscow Institute of Physics and Technology. In all, he has published 162 articles and produced 35 patents.
Evgeny specializes in mass spectrometry and ion processes as well as proteomics and petroleomics. His current research activities include supercomputer modeling of ion cloud behavior in accumulation and transportation of ions. Using mass spectrometry, he researches proteomes within physical liquids found in the human body through long isolation. He also develops the fundamental basis for quantitative analysis by mass spectrometry of the average copied proteins in the human body. Other research interests include analysis and classification of natural deposits of carbon through super-resolution mass spectrometry. He also develops and characterizes the dynamically harmonized Penning traps for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry.
Speaker 06
Prof. Neena Mitter
Centre Director, Centre for Horticultural Science, University of Queensland, Australia
Prof Neena Mitter, Director, Centre for Horticultural Science, Queensland Alliance for Agriculture and Food Innovation, the University of Queensland has been involved in molecular biology and biotechnology in Australia and India for over 20 years. Her scientific journey began as an agricultural scientist in India, where she learned first-hand the significance of agriculture in shaping the world, economically, socially, environmentally and politically. Her innovations creating change by research at UQ, namely ‘BioClay for crop protection’, ‘Nanovaccines for animal health’, and “Clonal propagation of avocado using plant stem cells” are ground breaking platform technologies impacting agricultural production, environmental sustainability and socio-economic dynamics of farming community. She is at the forefront of increasing UQ’s international presence, to support global collaborations in priority geographies, particularly India. With increased scrutiny on use of chemicals as crop and animal disease control agents; she is focused on developing clean technologies for the horticulture of tomorrow.
Read more…
The recognition received by Prof Mitter, including Young Scientist Award from the Prime Minister of India, Queensland International Fellowship, Gates Grand Challenges Explorations Award, Women in QAAFI Award, and more recently ‘Women in Technology Outstanding Life Sciences Award’ are testament to her achievements, leadership, and passion to enrich the UQ community. She is actively contributing into UQs vision of diversity and inclusion and is also the Deputy Council member of the Leadership and Diversity Council (https://www.leadershipdiversity.org.au/)
Speaker 06
Prof James Van Etten
William Allington Distinguished Professor of Plant Pathology, University of Nebraska-Lincoln, USA
Research in the Van Etten laboratory focuses on the isolation and characterization of large icosahedral, dsDNA-containing, plaque-forming viruses that infect certain unicellular, eukaryotic chlorella-like green algae. These viruses are ubiquitous in fresh water from all over the world. The chlorella viruses have genomes as large as 370 kb that contain as many as 400 protein encoding- and 16 tRNA encoding-genes. Besides their large genomes, the chlorella viruses have other unexpected features: (i) They encode multiple DNA methyltransferases and DNA restriction endonucleases. (ii) Unlike other glycoprotein-containing viruses, chlorella viruses encode most, if not all, of the components required to glycosylate their proteins. (iii) Many chlorella virus-encoded proteins are either the smallest or among the smallest proteins of their class. Consequently, these proteins serve as models for mechanistic and structural studies. Infection by the chlorella viruses resembles bacterial infection by tailed bacteriophages in many respects.
Speaker 06
Dr Kristiina Mäkinen
University Lecturer, Department of Microbiology, University of Helsinki, Finland
The research work in Dr Kristiina Mäkinen’s laboratory at the University of Helsinki, Finland, focuses on molecular elucidation of the different stages of potyvirus infection and investigates localization and coordination of viral processes within the infected plant cells. This work has revealed various cellular pathways functioning during infection and led to identification of infection-associated molecular complexes essential for potyviral replication, translation, RNA silencing suppression and virion encapsidation. Dr. Mäkinen has presented these research findings in many international congresses as an invited speaker and published over 70 research articles, reviews and book chapters in respected international journals. Read more…
Speaker 06
Prof. Øystein Evensen
Professor, Department of Paraclinical Sciences, Norwegian University of Life Sciences, Norway
Øystein Evensen is head of the research group “Host-pathogen interactions in infection and immunity” at the Faculty of Veterinary Medicine. He got his degree in veterinary medicine from the Norwegian School of Veterinary Science in 1984 and his PhD in pathology from the same institution in 1987.
He worked for more than 10 years after his PhD as post-doc and research scientist at the Norwegian Veterinary Institute in Oslo, Norway, more than 7 years in pharmaceutical industry (1995-2002) with development of vaccines for finfish, particularly salmon. Over the last 18 years he has been full professor at the Norwegian University of Life Sciences, Faculty of Veterinary Medicine, where he heads a research group of more than 15 people, that includes 2 associate professors, research scientists, post docs and PhD students.
Read more…
The research groups is focusing on viral and bacterial diseases of farmed salmon, mechanisms of infection and vaccine development and is funded through projects from the Research Council of Norway and the EU Framework program. Main research focus over the last years has been cardiomyopathy syndrome of Atlantic salmon the research group was the first to described the cause of the disease, piscine myocarditis virus. Evensen’s groups also work on immunoprophylacitc principles against sea lice infection in Atlantic salmon.
The research group is heavily involved in research and capacity building in Africa (Zambia, Tanzania, Kenya and Uganda) through a NORHED (NORAD)-funded research programme, focusing on capacity building and training of young research scientists in the south. Through this involvement, there has been a lot of focus on tilapia lake virus, diagnostic methods and pathogenesis studies.
The research group also uses model fish for study of infection mechanisms and pathogenic events of disease (pathogenesis) related mainly to viral infections. Here the group has used reverse genetics made viruses to understand virulence mechanisms and virulence factors that the virus employ to circumvent antiviral responses of the host.
Speaker 06
Dr Karyn Johnson
Associate Professor, School of Biological Sciences, University of Queensland, Australia
Invertebrate Virology
Insects are commonly infected with viruses. We study the interactions between viruses and their insect or arthropod hosts. Viruses are obligate parasites, that is, they are completely dependent on the host cell machinery to complete their replication cycle. During infection, viruses commonly cause pathology in the host. For these reasons, viruses and hosts are in a constant evolutionary arms race. The host evolves antiviral mechanisms to prevent virus infection, while the virus adapts to overcome these host responses. Insects are ideal hosts to understand both the host response and the virus mechanisms for controlling the host.
Read more…
My research group investigates the interactions between viruses and insects, primarily using Drosophila as a model. In this model we can control the genetics of both the host and the virus to tease apart the contribution of each partner to the interaction. We discovered that a bacterium, Wolbachia, mediated antiviral protection in insects. We have several projects investigating both the mechanisms that protect the insects from virus infection and the impact of this protection on virus transmission.
Speaker 06
Prof. Cameron Myhrvold
Assistant Professor of Molecular Biology at Princeton University, USA
Cameron Myhrvold is an Assistant Professor of Molecular Biology at Princeton University. His work specializes in the development of CRISPR-based technologies for studying RNA, with an emphasis on detecting and destroying RNA viruses. He received a PhD in Systems Biology from Harvard in 2016. His PhD studies in synthetic biology and nucleic acid nanotechnology, supported by a Fannie and John Hertz Foundation fellowship, involved the development of three technologies that demonstrated a variety of applications for self-assembled nanostructures. During his postdoc, he turned his attention towards the RNA-targeting CRISPR effector protein Cas13, where he has led or co-led the development of four Cas13-based technologies, including CARMEN, CARVER, and SHINE.
Speaker 06
Prof. Mzia Kutateladze
Director, G. Eliava Institute of Bacteriophages, Microbiology and Virology, Georgia
Dr. Mzia Kutateladze represents the world-renown G. Eliava Institute of Bacteriophages, Microbiology and Virology, headquartered in Tbilisi, Georgia. Currently, she is the Director of Eliava Institute, as well as the President of the Eliava Foundation, a collection of commercial spin-offs. She oversees, coordinates and manages the research directions and programs of the Institute. She is the author or co-author of more than 80 scientific papers. Her scientific background is in microbiology and molecular biology, bacteriophage research and application. Dr. Kutateladze was a manager and a leading scientist of number of scientific research projects. She is serving as a project and papers reviewer for national and international funding agencies and scientific journals.
Speaker 06
Prof. Curtis Suttle
FRSC, Professor, Distinguished University Scholar, University of British Columbia, Canada
Curtis Suttle’s research focuses on viruses and their diversity, evolution, and function in the global system, with an emphasis on the oceans. As a frequently invited speaker at Universities and International symposia, as well as a commentator in print, video and television, he makes a persuasive case that viruses encompass much of the genetic diversity on Earth and are major drivers of global biogeochemical cycles. His work has helped shift the paradigm from viruses being enemies and agents of death, to the perspective that viruses are essential to life on Earth. His scholarship has been recognized by being appointed as a Fellow of the Royal Society of Canada and American Academy of Microbiology, as well as appointments with the Canadian Institute for Advanced Research, the Peter Wall Institute for Advanced Research, and the Institute for Advanced Studies at the Hong Kong University of Science and Technology. As well as being a Distinguished University Scholar and Wall Scholar at the University of British Columbia, he is a recipient of the A.G. Huntsman, Timothy R. Parsons and G. Evelyn Hutchinson Medals in Marine Science.
Speaker 06
Prof. Stephanie Karst
Associate Professor, Emerging Pathogens Institute, University of Florida, USA
Noroviruses are responsible for significant human disease, causing over 90% of nonbacterial epidemic gastroenteritis worldwide. It is also a major cause of severe diarrhea in children in developing nations and has been estimated to cause 200,000 deaths in this population each year. Primary human norovirus infection does not elicit lasting protective immunity, a fact that could greatly affect the efficacy of vaccination strategies. Our long term goal is to elucidate the mechanisms by which noroviruses avoid the induction of protective immunity, ultimately translating this knowledge into successful vaccination approaches. Little is known regarding the pathogenesis of human noroviruses or the immune responses that control them because there has previously been no small animal model of norovirus infection. Read more…
Speaker 06
Dr. Egbert Mundt
Head of Global Poultry Vaccine R&D, Boehringer Ingelheim, Germany
Dr. Egbert Mundt graduated as DVM from the Veterinary College of the Humboldt University Berlin, in 1989. He started his work in poultry virology at the Friedrich Loeffler Institute, Insel Riems, Germany at the same year. In 1992, he became staff scientist and later group leader at the Federal Research Institute for Animal Health, Insel Riems, Germany, until 2006. He obtained his PhD in molecular virology at the Veterinary College of the University Giessen in 1995. Dr Mundt was visiting scientist at the Veterinary College of the University of Maryland in 1995. Next, in 2000 he obtained the title Specialist in Veterinary Virology. Read more…
Speaker 06
Prof. Christina Wege
Head of Research Unit Molecular & Synthetic Plant Virology, University of Stuttgart, Germany
Prof. Dr. Christina Wege has been at the University of Stuttgart since 1994 and is specifically interested in plant viruses. The Research Unit Molecular and Synthetic Plant Virology focuses on plant viral building blocks for smart materials and bionanotechnoloy in various areas of research, on molecular interactions between plants and viruses in single and mixed infections and on phytoviral engineering.
Speaker 06
Dr. Fabien Zoulim
Professor of Medicine, Lyon University, Institut Universitaire de France; Medical Director, Hepatology Department at the Hospices Civils de Lyon; Scientific Director, Viral Hepatitis Research Laboratory, INSERM U1052, Cancer Research Center of Lyon, France
Fabien Zoulim obtained his M.D. in Gastroenterology and Hepatology in Lyon Medical School in 1991. He has also obtained a PhD in Molecular and Cellular Biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia. He is Professor of Medicine at Lyon I University since 1997. He is currently Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology of INSERM Unit 1052 where he is leading the team on ‘Antiviral therapy of viral hepatitis’. Dr Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. Read more…
Speaker 06
Prof. Kari Nadeau
Naddisy Foundation Professor of Pediatric Food Allergy, Immunology and Asthma, Professor of Pediatrics, Senior Fellow at the Woods Institute and Professor, by courtesy, of Otolaryngology and of Epidemiology and Population Health at LPCH
Dr. Kari Nadeau is the Naddisy Foundation Endowed Professor of Medicine and Pediatrics and, Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. She is Section Chief in Asthma and Allergy in the Pulmonary, Allergy and Critical Care Division at Stanford. She is the Sr. Director of Clinical Research for the Division of Hospital Medicine.
Read more…
For more than 30 years, she has devoted herself to understanding how environmental and immune/genetic factors affect allergies, immune tolerance, and asthma. She and her team are focused in areas of global climate change and health by studying air pollution and wildfire exposures, particularly in underserved areas. As one of the globe’s foremost experts in adult and pediatric allergy, immunology, and asthma, her research is laying the groundwork for a variety of potential future therapies to prevent and cure allergies and asthma. Dr. Nadeau leads a team of specialists spanning allergy, asthma, and immunology across Stanford University. She has been a pioneer in the field of Translational Allergy and Immunology, both defining the mechanism of new therapies and then translating them clinically to make transformative changes for patients and their families. She has led research in oncology, transplant, infectious diseases, COVID, and autoimmune trials and is a member of the National Steering Committee for the intramural clinical research programs at the NIH Immune Tolerance Network. She and her team have been awarded many patents and have started 4 biotech companies in the Bay Area under Stanford patents and has worked in industry to shepherd two drugs through the FDA to approval. She also is an author of the Lancet Countdown in Global Climate Change 2020 and the book: The End of Food Allergy (published 2020).
Dr. Nadeau received her MD and PhD from Harvard Medical School through the NIH MSTP program. She completed a residency in pediatrics at Boston Children’s Hospital and a clinical fellowship in allergy, asthma and immunology at Stanford and at University of California, San Francisco.
Dr. Nadeau has served as a FDA consultant and a reviewer for NIH Study Sections. Also, she served on the environmental health policy committee for the American Thoracic Society, and serves on the Data and Safety Monitoring Board (DSMB) of the National Heart, Lung, and Blood Institute (NHLBI), and is a fellow in the American Academy of Allergy, Asthma, and Immunology (AAAAI). She started the Gordon Research Conference for Food Allergy and Chaired the first inaugural conference (2018). She is Chair of the Board of Scientific Counselors for the NIH Clinical Center (2018-2021). She is a member of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP), the medical board of the American Lung Association in California, the Scientific Advisory Board of the EPA, and is currently working with the US Congress, the WHO, International Wildfire Policy Group, CUGH, and CA Governor’s office on Global Climate Change emergency preparedness plans.
In addition to her above involvements, Dr. Nadeau contributes on multiple editorial boards for high impact journals and to date published over 300 peer-reviewed publications, and is a reviewer for high impact journals in basic science and clinical medicine (Nature, Nature Medicine, Science, Science Translational Medicine, Lancet, NEJM, JAMA, Allergy, JACI).
She is also passionate about breaking down health barriers and creating meaningful change for children and adults in underserved areas and has developed outreach and educational programs with partners in East Palo Alto, Inner City Chicago, Harlem, and San Francisco.
Her work has been recognized with numerous grants and awards. She has collaborated with many organizations and institutions. Through FARE, CoFAR, WHO, the United Nations and other partnerships, she collaborates with colleagues from institutions around the globe.
Speaker 06
Prof. Neil Ferguson
Vice-Dean (Academic Development), Faculty of Medicine, Imperial College London
My research aims to improve understanding of the epidemiological factors and population processes shaping infectious disease spread in human and animal populations. A key practical focus is the analysis and optimisation of intervention strategies aimed at reducing transmission or disease burden. Much of my work is applied, informing disease control policy-making by public and global health institutions.
Read more…
With recent advances in data availability (both epidemiological and molecular) and affordable high-performance computing, mathematical models of infectious disease spread now offer the potential to provide predictive, quantitative analyses of alternative disease control and treatment strategies, as well as qualitative insight into the complex non-linear processes shaping pathogen replication and evolution. An important strand of my research program is therefore to develop the statistical and mathematical tools necessary for such increasingly sophisticated models to be rigorously tested and validated against epidemiological, molecular and experimental data. The breadth of my research interests reflects my belief that comparative analyses of different host-pathogen systems can provide powerful insights into the population processes common to many infectious diseases, while highlighting how key differences in disease biology, route of transmission or host population structure determine observed differences in patterns of infection.
Speaker 06
Dr. Emilia Liana Falcone
Director, IRCM Post-COVID-19 research clinic; Director, Microbiome and Mucosal Defense Research Unit at the Montreal Clinical Research Institute (IRCM), Canada
Dr. Emilia Liana Falcone is the Director of the IRCM Post-COVID-19 research clinic and the
Director of the Microbiome and Mucosal Defense Research Unit at the Montreal Clinical
Research Institute (IRCM). She is also an Assistant Clinical Professor in the Department of
Medicine at Université de Montréal, an infectious diseases specialist at Centre Hospitalier de
‘Université de Montréal (CHUM), and holds a Canada Research Chair in the Role of the
Microbiome in Primary Immunodeficiency. Read more…
Dr. Falcone studied medicine at McGill University in Montreal and obtained a specialization in
internal medicine at Tufts Medical Center in Boston, after which she spent 8 years at the
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
During this time, she completed a fellowship in Infectious Diseases while also obtaining a Ph.D.
at the University of Cambridge as an NIH-Oxford-Cambridge scholar. She then became an
Assistant Clinical Investigator at the NIH as a recipient of the NIAID Transition Program in
Clinical Research award and developed a unique research program focused on the role of the
microbiota in the modulation of inflammatory complications in patients with inborn errors of
immunity. In particular, Dr. Falcone demonstrated in mice and humans that NADPH oxidase 2
defects, which cause chronic granulomatous disease (CGD), shape the intestinal microbiota and
metabolome, and that colitis severity in CGD mice depends on the microbiota established at
birth. Dr. Falcone was recruited to the IRCM at the end of 2018 where she established a
translational research program centered on 2 research objectives: 1) defining the role of the
intestinal microbiota in driving disease severity in patients with inborn errors of immunity and
2) evaluating the impact of inborn errors of immunity on the function of the intestinal
microbiota. During the COVID-19 pandemic, Dr. Falcone established the IRCM Post-COVID-19
(IPCO) research clinic, the first clinic of its kind in Montreal. The IPCO research clinic integrates
the clinical evaluation of post-acute COVID-19 sequelae with a research protocol
(clinicaltrials.gov; NCT04736732) and biobank aimed at understanding the mechanisms
underlying the pathogenesis of the post-COVID-19 condition.
Speaker 06
Prof. Sylvain Moineau
Canada Research Chair in Bacteriophages, Université Laval, Canada
Dr. Sylvain Moineau, Canada Research Chair in Bacteriophages, aims to improve knowledge of the biology of phages. He is using an integrated approach that combines genomic and proteomic data, as well as data from other fields, to better understand interactions between phages and bacteria.
He aims to develop new tools that would eliminate bacteriophages in dairy fermentation and that could be used as antibacterials in public health and in a wide variety of industries.
Moineau’s research will go far towards increasing the friendly use of bacteriophages and to reducing their more harmful traits.